As Big Pharma patents age, smaller biotechs hold the most clinical-stage assets
Big Pharma is under growing pressure to restock its drug pipelines as an unusually large wave of patent expirations threatens hundreds of billions of dollars in revenue. That urgency is intensifying...To view the full article, register now.
Already a subscriber? Click here to view full article